Von Willebrand factor human
- Generic Name
- Von Willebrand factor human
- Brand Names
- Vonvendi, Wilate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 109319-16-6
- Unique Ingredient Identifier
- ZE22NE22F1
- Background
The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII). Exogenous sources of vWF are used to restore fun...
- Indication
The von Willebrand factor (vWF) is indicated to manage and control bleeding episodes in adults with von Willebrand disease. It is also used for perioperative management of bleeding in these patients. It is also used for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand t...
- Associated Conditions
- Bleeding, Perioperative Blood Loss
- Associated Therapies
- Perioperative bleeding management therapy
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 12
- Registration Number
- NCT04953884
- Locations
- 🇲🇰
PHI University Clinic for Child Diseases, Skopje, North Macedonia
🇷🇺FSBI National Research Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇺🇦Danylo Halytsky Lviv National Medical University, Communal Institution of Lviv Regional Council "Western Ukrainian Specialized Children's Medical Centre", Lviv, Ukraine
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 120
- Registration Number
- NCT04555785
- Locations
- 🇨ðŸ‡
University Hospital Basel, Basel, Switzerland
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 43
- Registration Number
- NCT04052698
- Locations
- 🇧🇾
Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
🇺🇦State Institution "National Children's Specialized Hospital "OKHMATDYT" of the Ministry of Health of Ukraine," Center of Hemostasis Pathology, Kyiv, Ukraine
🇧🇬"Specialized Hospital for Active Treatment of Haematological Diseases" EAD, Sofia, Sofia, Bulgaria
Von Willebrand Factor Concentrate During ECMO Support
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Tirol Kiniken GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT03613584
- Locations
- 🇦🇹
Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine, Innsbruck, Austria
🇦🇹Medical University Innsbruck / Department for General and Surgical Critical Care Medicine, Innsbruck, Austria
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 11
- Registration Number
- NCT03376516
- Locations
- 🇷🇺
Kirov SSC Hematology and Transfusiology, Kirov, Russian Federation
🇺🇦"National Children's Specialized Clinic "OKHMATDYT", Kyiv, Ukraine
🇺🇦"Western Ukrainian Specialized Children's Medical Center", Lviv, Ukraine
INdividualized ITI Based on Fviii(ATE) Protection by VWF
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 1
- Registration Number
- NCT03204539
- Locations
- 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸University of California, Davis, Sacramento, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 57
- Registration Number
- NCT02954575
- Locations
- 🇧🇬
Specialized Hospital for Active Treatment "Joan Pavel", Sofia, Bulgaria
ðŸ‡ðŸ‡ºNational Haemophilia Centre, Budapest, Hungary
🇵🇱Korczowski Bartosz Gabinet Lekarski, Rzeszow, Poland
Type 3 Von Willebrand International Registries Inhibitor Prospective Study
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Fondazione Angelo Bianchi Bonomi
- Target Recruit Count
- 265
- Registration Number
- NCT02460458
- Locations
- 🇮🇷
Seid-ol-Shohada Hospital - Hemophilia Center - Esfahan University of Medical Science, Esfahan, Iran, Islamic Republic of
🇮🇷Hemophilia- Thalassaemia Center of Mashhad (Sarvar Clinic) - Mashad University of Medical Science, Mashhad, Iran, Islamic Republic of
🇮🇷Iranian Hemophilia Comprehensive Treatment Centre - Iranian Hemophilia Society, Tehran, Iran, Islamic Republic of
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004667
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.